March 5, 2018 / 5:08 PM / 7 months ago

BRIEF-GSK Says ViiV Healthcare Reports Positive Dolutegravir Data

March 5 (Reuters) - Glaxosmithkline Plc:

* GLAXOSMITHKLINE PLC - VIIV HEALTHCARE ANNOUNCES POSITIVE NEW DOLUTEGRAVIR DATA FOR TREATMENT OF PEOPLE LIVING WITH HIV CO-INFECTED WITH TUBERCULOSIS

* GLAXOSMITHKLINE PLC - DOLUTEGRAVIR WHEN ADMINISTERED AT 50MG TWICE-DAILY WITH DUAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, WAS EFFECTIVE

* GLAXOSMITHKLINE PLC - DOLUTEGRAVIR WAS WELL-TOLERATED IN HIV/TB CO-INFECTED ADULTS RECEIVING RIFAMPIN-BASED TB THERAPY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below